Since MyoKardia Inc. (NASDAQ:MYOK) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of both companies.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MyoKardia Inc.	33.56M	72.60	67.70M	-1.59	0.00
EyePoint Pharmaceuticals Inc.	5.86M	32.91	89.44M	-1.35	0.00

Demonstrates MyoKardia Inc. and EyePoint Pharmaceuticals Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 has MyoKardia Inc. and EyePoint Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
MyoKardia Inc.	-201.73%	-19.9%	-17.2%
EyePoint Pharmaceuticals Inc.	-1,526.28%	-414.6%	-142.9%

Volatility and Risk

A beta of 2.42 shows that MyoKardia Inc. is 142.00% more volatile than Standard & Poor’s 500. In other hand, EyePoint Pharmaceuticals Inc. has beta of 2.02 which is 102.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of MyoKardia Inc. are 8.6 and 8.6 respectively. Its competitor EyePoint Pharmaceuticals Inc.’s Current Ratio is 2.6 and its Quick Ratio is 2.6. MyoKardia Inc. can pay off short and long-term obligations better than EyePoint Pharmaceuticals Inc.

Analyst Recommendations

In next table is shown MyoKardia Inc. and EyePoint Pharmaceuticals Inc.’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
MyoKardia Inc.	0	0	1	3.00
EyePoint Pharmaceuticals Inc.	0	0	0	0.00

MyoKardia Inc. has an average target price of $85, and a 57.85% upside potential.

Insider and Institutional Ownership

Roughly 92.4% of MyoKardia Inc. shares are held by institutional investors while 62.3% of EyePoint Pharmaceuticals Inc. are owned by institutional investors. 0.6% are MyoKardia Inc.’s share held by insiders. Comparatively, EyePoint Pharmaceuticals Inc. has 0.5% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
MyoKardia Inc.	14.82%	23.78%	-14.83%	-13.92%	-14.35%	4.83%
EyePoint Pharmaceuticals Inc.	-2.21%	21%	28.64%	25%	150%	40.21%

For the past year MyoKardia Inc. has weaker performance than EyePoint Pharmaceuticals Inc.

Summary

MyoKardia Inc. beats EyePoint Pharmaceuticals Inc. on 9 of the 11 factors.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, a product candidate that is intended to increase cardiac muscle contractility to normal levels in genetic DCM patients through a different mechanism than that of MYK-491; and LUS-1, a product candidate, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart. The company has a strategic collaboration with Sanofi S.A. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.